Botulinum toxin: does the black box warning justify change in practice?
The Hospital for Sick Children, Bloorview Research Institute, University of Toronto, Toronto, Ontario, Canada.
Unni G
UG
Narayanan
D016907:Adverse Drug Reaction Reporting Systems; D018726:Anti-Dyskinesia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000009:adverse effects* / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000627:therapeutic use; D002547:Cerebral Palsy / Q000534:rehabilitation*; D002648:Child; D002986:Clinical Trials as Topic; D004348:Drug Labeling; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007273:Injections, Intramuscular; D012306:Risk; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D018726:Anti-Dyskinesia Agents; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A